Ohnmacht, SA;
Marchetti, C;
Gunaratnam, M;
Besser, RJ;
Haider, SM;
Di Vita, G;
Lowe, HL;
... Neidle, S; + view all
(2015)
A G-quadruplex-binding compound showing anti-tumour activity in an in vivo model for pancreatic cancer.
Scientific Reports
, 5
, Article 11385. 10.1038/srep11385.
![[thumbnail of A G-quadruplex-binding compound showing anti-tumour activity in an in vivo model for pancreatic cancer..pdf]](https://discovery.ucl.ac.uk/style/images/fileicons/text.png) |
Text
A G-quadruplex-binding compound showing anti-tumour activity in an in vivo model for pancreatic cancer..pdf Download (1MB) |
Abstract
We report here that a tetra-substituted naphthalene-diimide derivative (MM41) has significant in vivo anti-tumour activity against the MIA PaCa-2 pancreatic cancer xenograft model. IV administration with a twice-weekly 15 mg/kg dose produces ca 80% tumour growth decrease in a group of tumour-bearing animals. Two animals survived tumour-free after 279 days. High levels of MM41 are rapidly transported into cell nuclei and were found to accumulate in the tumour. MM41 is a quadruplex-interactive compound which binds strongly to the quadruplexes encoded in the promoter sequences of the BCL-2 and k-RAS genes, both of which are dis-regulated in many human pancreatic cancers. Levels of BCL-2 were reduced by ca 40% in tumours from MM41-treated animals relative to controls, consistent with BCL-2 being a target for MM41. Molecular modelling suggests that MM41 binds to a BCL-2 quadruplex in a manner resembling that previously observed in co-crystal structures with human telomeric quadruplexes. This supports the concept that MM41 (and by implication other quadruplex-targeting small molecules) can bind to quadruplex-forming promoter regions in a number of genes and down-regulate their transcription. We suggest that quadruplexes within those master genes that are up-regulated drivers for particular cancers, may be selective targets for compounds such as MM41.
Archive Staff Only
 |
View Item |
